U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H29N7O3.ClH
Molecular Weight 487.982
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LX-7101 HYDROCHLORIDE

SMILES

Cl.CN(C)C(=O)OC1=CC=CC(NC(=O)C2(CN)CCN(CC2)C3=NC=NC4=C3C(C)=CN4)=C1

InChI

InChIKey=ZQRGQMCNRINKRN-UHFFFAOYSA-N
InChI=1S/C23H29N7O3.ClH/c1-15-12-25-19-18(15)20(27-14-26-19)30-9-7-23(13-24,8-10-30)21(31)28-16-5-4-6-17(11-16)33-22(32)29(2)3;/h4-6,11-12,14H,7-10,13,24H2,1-3H3,(H,28,31)(H,25,26,27);1H

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/25589936

LX-7101 (Lexicon Pharmaceuticals) was advanced to Phase-I clinical trials for treatment open-angle glaucoma or ocular hypertension. This drug is a potent inhibitor of LIM-kinase 2 (LIMK2) kinase and inhibits to less extent LIMK1 and Rho-associated protein kinase 2 (ROCK2).

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 4.3 nM [IC50]
Inhibitor
8504
 32.0 nM [IC50]
Inhibitor
8504
 32.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase I
438
Unknown

Approved Use

Unknown
Primary
Phase I
438
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
10400 nM
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/25589936
0.03 mg single, topical
dose: 0.03 mg
route of administration: Topical
experiment type: SINGLE
co-administered:
LX7101 cornea
Rattus norvegicus
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
45 μM × h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/25589936
0.03 mg single, topical
dose: 0.03 mg
route of administration: Topical
experiment type: SINGLE
co-administered:
LX7101 cornea
Rattus norvegicus
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
1PlusChem LLC
1P008U31
https://www.1pchem.com/search?query=1P008U31
AChemBlock
M15681
http://www.achemblock.com/catalogsearch/result/?q=M15681
ApexBio Technology
B5863
https://www.apexbt.com/catalogsearch/result/?q=B5863
AstaTech
C14316
http://astatechinc.com/CPSResult.php?CRNO=C14316
BLD Pharm
BD629971
http://www.bldpharm.com/search/Search.html?keyword=BD629971
Cayman Chemical
21209
http://www.caymanchem.com/app/template/Product.vm/catalog/21209
Chem Scene
CS-5103
http://www.chemscene.com/goproductList/searchProductList?productObj=CS-5103
eMolecules
72973106
https://orderbb.emolecules.com/search/#?query=72973106
eMolecules
93437748
https://orderbb.emolecules.com/search/#?query=93437748
Excenen
EX-A2288
http://www.excenen.com/searchresultlist.php?id=EX-A2288
mcule
MCULE-8096869004
https://mcule.com/MCULE-8096869004/
MedChem Express
HY-12659
https://www.medchemexpress.com/search.html?q=HY-12659&ft=&fa=&fp=
Molnova
M10664
https://www.molnova.com/en/serch-list.html?keywords=M10664
MolPort
MolPort-044-561-838
https://www.molport.com/shop/molecule-link/MolPort-044-561-838
MolPort
MolPort-046-416-915
https://www.molport.com/shop/molecule-link/MolPort-046-416-915
MuseChem
I000697
https://www.musechem.com/product/I000697.html
MuseChem
R066798
https://www.musechem.com/product/R066798.html
ShangHai Biochempartner
BCP000294
http://www.biochempartner.com/search_BCP000294
ShangHai Biochempartner
BCP02298
http://www.biochempartner.com/search_BCP02298
PubMed

PubMed

TitleDatePubMed
Design, synthesis and biological characterization of selective LIMK inhibitors.
2015-09-15
Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma.
2015-01-08
Patents

Patents

08193202
2
08450332
2
08735408
2
20090264450
2
20120122898
2
20120329818
2
8193202
2
8450332
2
8735408
2
JP2013541588A
2
WO2009131940A1
2
WO2012061565A1
2
WO2015150337A1
2

Sample Use Guides

In Vivo Use Guide
Low dose LX7101: Days 1-3: once daily dose in study eye (eye with highest IOP); Days 4-7: once daily dose in study eye (eye with highest IOP) and fellow eye (other eye); Days 8-14: twice daily dose in study eye (eye with highest IOP) and fellow eye High dose LX7101: Days 1-3: once daily dose in study eye (eye with highest IOP); Days 4-7: once daily dose in study eye (eye with highest IOP) and fellow eye (other eye); Days 8-14: twice daily dose in study eye (eye with highest IOP) and fellow eye (other eye).
Route of Administration: Other
In Vitro Use Guide
In vitro assay was used to identify LIMK and ROCK inhibitors. For kinetic studies, the final LX7101concentrations varied from 0 to 100 nM.
Name Type Language
LX-7101 HYDROCHLORIDE
Common Name English
LX-7101 HCL
Preferred Name English
LX7101 HYDROCHLORIDE
Code English
CARBAMIC ACID, N,N-DIMETHYL-, 3-(((4-(AMINOMETHYL)-1-(5-METHYL-7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)-4-PIPERIDINYL)CARBONYL)AMINO)PHENYL ESTER, HYDROCHLORIDE
Systematic Name English
Code System Code Type Description
CAS
1374644-80-0
Created by admin on Mon Mar 31 21:08:35 GMT 2025 , Edited by admin on Mon Mar 31 21:08:35 GMT 2025
NON-SPECIFIC STOICHIOMETRY
FDA UNII
S5G8WJ39X9
Created by admin on Mon Mar 31 21:08:35 GMT 2025 , Edited by admin on Mon Mar 31 21:08:35 GMT 2025
PRIMARY
PUBCHEM
56962368
Created by admin on Mon Mar 31 21:08:35 GMT 2025 , Edited by admin on Mon Mar 31 21:08:35 GMT 2025
PRIMARY
ACTIVE MOIETY
Structure of LX-7101
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966